Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: A phase 1 study in japanese patients with previously treated non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 10, Issue 2, 2015, Pages 346-352

  Okamoto, Isamu ^a,b   Miyazaki, Masaki ^a,c   Takeda, Masayuki ^a   Terashima, Masaaki ^a,d   Azuma, Koichi ^a,e   Hayashi, Hidetoshi ^a,f   Kaneda, Hiroyasu ^a   Kurata, Takayasu ^a,g   Tsurutani, Junji ^a   Seto, Takashi ^h   Hirai, Fumihiko ^h   Konishi, Koichi ^h   Sarashina, Akiko ⁱ   Yagi, Nobutaka ^h   Kaiser, Rolf ^j   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c Suita Municipal Hospital   (Japan)

^d KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^e KURUME UNIVERSITY HOSPITAL   (Japan)

^f KISHIWADA CITY HOSPITAL   (Japan)

^g KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

Clinical trials; Docetaxel; Japanese; Nintedanib; Non small cell lung cancer; Pharmacokinetics; Phase I

Indexed keywords

ALANINE AMINOTRANSFERASE; DOCETAXEL; LIVER ENZYME; NINTEDANIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; TAXOID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; BLEEDING; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERTENSION; JAPANESE (PEOPLE); LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PERFORATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; THROMBOEMBOLISM; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; JAPAN; LUNG NEOPLASMS; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INDOLES; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; TAXOIDS;

EID: 84922221042     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000395     Document Type: Article

References (26)

1. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer, version 4. Available at: http://www.nccn.org/. Accessed August 31, 2014
2. Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K. The role of angiogenesis in solid tumours: an overview. Eur J Intern Med 2009;20:663-671
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550
4. Soria JC, Mauguen A, Reck M, et al.; Meta-Analysis of Bevacizumab in Advanced NSCLC Collaborative Group. Systematic review and metaanalysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24:20-30
5. Amini A, Masoumi Moghaddam S, Morris DL, Pourgholami MH. The critical role of vascular endothelial growth factor in tumor angiogenesis. Curr Cancer Drug Targets 2012;12:23-43
6. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257
7. Raica M, Cimpean AM. Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy. Pharmaceuticals 2010;3:572-599
8. Saylor PJ, Escudier B, Michaelson MD. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin Genitourin Cancer 2012;10:77-83
9. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-4782
10. Reck M, Kaiser R, Mellemgaard A, et al.; LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143-155
11. Okamoto I, Kaneda H, Satoh T, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010;9:2825-2833
12. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311-319
13. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-3546
14. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-4252
15. TAXOTERE [package inserts]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2013
16. Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013;108:1034-1041
17. van Der Veldt AA, Boven E, Helgason HH, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008;99:259-265
18. Park SJ, Choi IK, Seo HY, et al. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Acta Haematol 2007;118:219-221
19. Sakai M, Miyazaki Y, Matsuo E, et al. Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. Int J Hematol 2009;89:319-325
20. Larson RA, Druker BJ, Guilhot F, et al.; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022-4028
21. Doebele RC, Conkling P, Traynor AM, et al. A phase I, open-label doseescalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2012;23:2094-2102
22. Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N. Phase I openlabel study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010;16:2881-2889
23. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29:3798-3804
24. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011;22:1374-1381
25. Bousquet G, Alexandre J, Le Tourneau C, et al. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormonerefractory prostate cancer patients. Br J Cancer 2011;105:1640-1645
26. Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly-a mini-review. Gerontology 2010;56:303-309